Table 3.
Epidemiologic determinants of CA125 levels among women with invasive non-mucinous tumors.
| CA 125 Classification |
Geometric mean (95% CI) |
P, linear* |
|||
|---|---|---|---|---|---|
| Low < 35 N=62 |
Intermediate 35–1750 N=435 |
High >1750 N=139 |
|||
| Menopausal status | |||||
| Pre | 23 (37.7%) | 112 (27.1%) | 34 (26.0%) | 320 (246, 417) | Ref. |
| Post, ≤10 years | 16 (26.2%) | 128 (30.9%) | 55 (42.0%) | 498 (390, 636) | 0.05 |
| Post, >10 years | 22 (36.1%) | 174 (42.0%) | 42 (32.1%) | 379 (303, 474) | 0.60 |
| Race | |||||
| White | 57 (93.4%) | 396 (93.8%) | 129 (96.3%) | 411 (357, 474) | |
| Non-white | 4 (6.6%) | 26 (6.2%) | 5 (3.7%) | 232 (130, 415) | 0.06 |
| Jewish ethnicity | |||||
| No | 57 (93.4%) | 374 (88.6%) | 108 (80.6%) | 378 (326, 438) | |
| Yes | 4 (6.6%) | 48 (11.4%) | 26 (19.4%)† |
600 (407, 885) | 0.04 |
| BMI | |||||
| <21.6 | 9 (14.8%) | 78 (18.6%) | 30 (22.7%) | 497 (361, 683) | |
| 21.6–23.7 | 13 (21.3%) | 90 (21.5%) | 26 (19.7%) | 427 (315, 578) | |
| 23.8–25.8 | 12 (19.7%) | 81 (19.3%) | 28 (21.2%) | 412 (301, 563) | |
| 25.9–30.1 | 13 (21.3%) | 82 (19.6%) | 29 (22.0%) | 342 (251, 466) | |
| >30.1 | 14 (23.0%) | 88 (21.0%) | 19 (14.4%) | 328 (240, 448) | 0.04 |
| Smoking status | |||||
| Never | 36 (59.0%) | 214 (51.1%) | 70 (51.9%) | 392 (323, 475) | Ref |
| Former | 19 (31.1%) | 165 (39.4%) | 52 (38.5%) | 429 (342, 537) | 0.61 |
| Current | 6 (9.8%) | 40 (9.5%) | 13 (9.6%) | 344 (220, 540) | 0.76 |
| OC use | |||||
| Never | 27 (44.3%) | 213 (50.5%) | 61 (45.2%) | 392 (321, 478) | |
| Ever | 34 (55.7%) | 209 (49.5%) | 74 (54.8%) | 409 (337, 496) | 0.66 |
| HRT use among postmenopausal |
|||||
| Never | 24 (64.9%) | 182 (62.1%) | 60 (64.5%) | 450 (366, 555) | Ref |
| Unopposed | 3 (8.1%) | 39 (13.3%) | 7 (7.5%) | 295 (182, 480) | 0.15 |
| Opposed | 10 (27.0%) | 50 (17.1%) | 22 (23.7%) | 435 (299, 634) | 0.78 |
| Other | 0 (0.0%) | 22 (7.5%) | 4 (4.3%) | 599 (307, 1168) | 0.42 |
| Parity | |||||
| 0 | 19 (31.7%) | 120 (28.4%) | 29 (21.5%) | 318 (244, 413) | |
| 1–2 | 29 (48.3%) | 171 (40.4%) | 48 (35.6%) | 364 (293, 452) | |
| 3–4 | 10 (16.7%) | 105 (24.8%) | 43 (31.9%) | 505 (385, 662) | |
| >4 | 2 (3.3%) | 27 (6.4%) | 15 (11.1%)† | 777 (465, 1298) | 0.0005 |
| Ovulatory cycles§ | |||||
| <312 | 13 (29.5%) | 69 (24.5%) | 21 (23.9%) | 354 (250, 502) | |
| 312–392 | 11 (25.0%) | 70 (24.8%) | 21 (23.9%) | 360 (254, 511) | |
| 393–451 | 9 (20.5%) | 73 (25.9%) | 21 (23.9%) | 355 (251, 502) | |
| >451 | 11 (25.0%) | 70 (24.8%) | 25 (28.4%) | 417 (296, 588) | 0.94 |
| Genital talc use | |||||
| No | 44 (72.1%) | 301 (71.5%) | 94 (70.1%) | 404 (343, 477) | |
| Yes | 17 (27.9%) | 120 (28.5%) | 40 (29.9%) | 384 (297, 497) | 0.71 |
| Endometriosis | |||||
| No | 50 (83.3%) | 379 (90.5%) | 124 (91.9%) | 420 (363, 486) | |
| Yes | 10 (16.7%) | 40 (9.5%) | 11 (8.1%) | 267 (172, 414) | 0.09 |
| Hysterectomy | |||||
| No | 58 (95.1%) | 374 (88.2%) | 122 (91.0%) | 406 (351, 469) | |
| Yes | 3 (4.9%) | 50 (11.8%) | 12 (9.0%) | 359 (235, 550) | 0.53 |
| Fibroids | |||||
| No | 46 (75.4%) | 326 (78.0%) | 103 (76.9%) | 419 (358, 491) | |
| Yes | 15 (24.6%) | 92 (22.0%) | 31 (23.1%) | 336 (251, 451) | 0.18 |
| Tubal ligation | |||||
| No | 54 (88.5%) | 370 (88.1%) | 109 (80.7%) | 382 (329, 443) | |
| Yes | 7 (11.5%) | 50 (11.9%) | 26 (19.3%) | 537 (368, 783) | 0.12 |
| Duration of IUD use§ | |||||
| Never | 42 (93.3%) | 237 (80.6%) | 71 (80.7%) | 354 (294, 427) | Ref |
| <2 years | 2 (4.4%) | 18 (6.1%) | 5 (5.7%) | 349 (174, 701) | 0.91 |
| ≥2 years | 1 (2.2%)† | 39 (13.3%) | 12 (13.6%) | 485 (299, 788) | 0.19 |
| Bladder infections§ | |||||
| No | 40 (87.0%) | 288 (98.0%) | 84 (95.5%) | 377 (318, 448) | |
| Yes | 6 (13.0%)† | 6 (2.0%) | 4 (4.5%) | 163 (68, 390) | 0.07 |
| Yeast infections§ | |||||
| No | 43 (93.5%) | 291 (99.0%) | 88 (100.0%) | 375 (316, 444) | |
| Yes | 3 (6.5%)† | 3 (1.0%) | 0 (0.0%) | 65 (16, 267) | 0.01 |
| Appendectomy§ | |||||
| No | 35 (76.1%) | 236 (80.3%) | 78 (88.6%) | 395 (328, 476) | |
| Yes | 11 (23.9%) | 58 (19.7%) | 10 (11.4%)† | 259 (175, 383) | 0.02 |
| Colitis§ | |||||
| No | 44 (95.7%) | 287 (97.6%) | 88 (100.0%) | 374 (315, 443) | |
| Yes | 2 (4.3%) | 7 (2.4%) | 0 (0.0%) | 127 (40, 406) | 0.05 |
| Personal history of breast cancer |
|||||
| No | 58 (95.1%) | 393 (93.1%) | 121 (89.6%) | 378 (328, 437) | |
| Yes | 3 (4.9%) | 29 (6.9%) | 14 (10.4%) | 809 (488, 1339) | 0.005 |
| Family history of breast or ovarian cancer |
|||||
| No | 49 (81.7%) | 322 (76.8%) | 90 (66.7%) | 353 (301, 414) | |
| Yes | 11 (18.3%) | 97 (23.2%) | 45 (33.3%)† | 603 (458, 794) | 0.001 |
*
p-value from linear regression adjusted for age and time between CA125 and diagnosis.
†
indicates a significant p-values (<0.05) from logistic regression models with either low CA125(<35) or high CA125 (>1775) as the dependent variable, adjusted for age and time between CA125 and diagnosis.
‡
p-value with adjustment by parity=0.11.
§
This data available for post-op study cases only.